The present disclosure is directed to methods for treating diseases for which cysteamine is indicated and compounds useful in such methods.

The present specification relates to a compound as a UBR box domain ligand. The present specification provides a small molecule compound that binds to the UBR box domain. Further, the present specification provides a composition for inhibiting UBR box domain substrate binding, including a ligand compound that binds to a UBR box domain, a pharmaceutical composition for treating UBR-related disease, and a use thereof.

The present specification relates to a compound as a UBR box domain ligand. The present specification provides a small molecule compound that binds to the UBR box domain. Further, the present specification provides a composition for inhibiting UBR box domain substrate binding, including a ligand compound that binds to a UBR box domain, a pharmaceutical composition for treating UBR-related disease, and a use thereof.

A light emitting element and an amine compound for the light emitting element are provided. The light emitting element includes a first electrode, a second electrode on the first electrode, and at least one functional layer between the first electrode and the second electrode The functional layer includes the amine compound and the luminous efficiency and service life of the light emitting element is improved.

A light emitting element and an amine compound for the light emitting element are provided. The light emitting element includes a first electrode, a second electrode on the first electrode, and at least one functional layer between the first electrode and the second electrode The functional layer includes the amine compound and the luminous efficiency and service life of the light emitting element is improved.

An organic light emitting device comprising a light emitting layer including a compound of Chemical Formula 1, and a first organic material layer including a compound of Chemical Formula 2.

##STR00001##

An organic light emitting device comprising a light emitting layer including a compound of Chemical Formula 1, and a first organic material layer including a compound of Chemical Formula 2.

##STR00001##

The present disclosure relates to compounds of Formula (I) and (II), compositions containing the compounds (alone or in combination with other agents), and their use to prevent, mitigate or treat a) damage induced by ionizing radiation, b) inflammation or c) cancer.

The present disclosure relates to compounds of Formula (I) and (II), compositions containing the compounds (alone or in combination with other agents), and their use to prevent, mitigate or treat a) damage induced by ionizing radiation, b) inflammation or c) cancer.

Disclosed are compounds that may be used to inhibit the action of fatty acid amide hydrolase (FAAH), monoacylglycerol lipase (MAGL) or dual FAAH/MAGL.